Valbiotis

Report Publication Announcement • Mar 11, 2021

VALBIOTIS: 2021 financial communication calendar

La Rochelle, March 11, 2021 (5:40 pm CET) VALBIOTIS (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today presents its 2021 financial communication calendar.

• March, 17: Annual Report (after market closing)
• May, 27: General Meeting (terms of participation to be specified later)
• September, 30: Half-year Report (after market closing)

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by

developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health world.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63).

VALBIOTIS is a member of the "BPI Excellence" network and received the «Innovative

Company» status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS: www.valbiotis.com

CONTACTS

CORPORATE COMMUNICATION I VALBIOTIS

Carole ROCHER / Marc DELAUNAY +33 5 46 28 62 58 I media@valbiotis.com

FINANCIAL COMMUNICATION I ACTIFIN

Stéphane RUIZ +33 1 56 88 11 14 I sruiz@actifin.fr

This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R20-018), these documents being available on the Company's website (www.valbiotis.com).

This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

Name: VALBIOTIS - ISIN code: FR0013254851 - Mnemonic code: ALVAL EnterNext© PEA-PME 150